NCLT Rejects Insolvency Petition Against Gaudium IVF

gaudium ivf & women health has announced that the National Company Law Tribunal (NCLT), New Delhi Bench, has rejected an insolvency petition filed against it. The order was passed by the Hon'ble NCLT on May 15, 2026, in the matter of M/s. Ramaa Capital versus the company.

The petition, bearing number C.P. (IB)/243/ND/2026, was filed under Section 9 of the Insolvency and Bankruptcy Code, 2016, by the operational creditor. The company received a copy of the said order on May 22, 2026.

Details of the Order

The disclosure was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key details regarding the regulatory order are outlined below:

Sr. No.	Particulars	Description
1.	Name of the authority	Hon'ble National Company Law Tribunal (NCLT)
2.	Nature and details of the action(s) taken or order(s) passed	The Hon'ble NCLT, New Delhi Bench, vide order dated May 15, 2026, has rejected the Petition of the Operational Creditor.
3.	Date of receipt of direction or order	May 22, 2026
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Not Applicable
5.	Impact on financial, operation or other activities of the listed entity	There is no impact on financial, operation or other activities of the Company.

Impact Assessment

The company has confirmed that the rejection of the petition has no quantifiable monetary impact on its financial, operational, or other activities. The information has been submitted to the exchanges and is also available on the company's website.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.00%	-7.79%	-14.51%	+24.02%	+24.02%	+24.02%

Gaudium IVF and Women Health Limited has issued a clarification to stock exchanges regarding recent share price movements, confirming that the volatility is purely market driven with no undisclosed material information pending. The company responded to specific queries from both BSE and NSE on April 16, 2026, addressing concerns about significant price fluctuations in its scrip.

Regulatory Compliance and Disclosure

The gaudium ivf & women health management emphasized its commitment to regulatory compliance, stating that all material events and information affecting company operations and performance have been disclosed to stock exchanges within stipulated timeframes. The company confirmed adherence to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency in all material disclosures.

Exchange Communications

The clarification was issued in response to formal communications from both major stock exchanges:

Exchange	Reference Number	Date
BSE Limited	L/SURV/ONL/PV/SJ/2026-2027/3750	April 16, 2026
NSE of India Limited	NSE/CM/Surveillance/16855	April 16, 2026

Company Position on Price Movement

The company categorically stated that there is no undisclosed price sensitive information or impending announcements that could influence share price or volume behavior. Management attributed the recent price movements entirely to market forces, dismissing speculation about any underlying corporate developments or material events that have not been publicly disclosed.

Future Disclosure Commitments

Gaudium IVF and Women Health Limited reaffirmed its commitment to maintaining transparency with stakeholders and regulatory bodies. The company assured continued prompt disclosure of all material events, information, and corporate actions as required under SEBI regulations. This commitment underscores the company's dedication to maintaining investor confidence through transparent communication practices.

The clarification was signed by Company Secretary and Compliance Officer Naveen Kumar, emphasizing the formal nature of the response and the company's commitment to regulatory compliance in addressing market concerns about share price volatility.